The Role of Botulinum Toxin Type A in the Radiation Fibrosis Syndrome: A Preliminary Report

ArticleinArchives of physical medicine and rehabilitation 89(3):417-21 · April 2008with6 Reads
Impact Factor: 2.57 · DOI: 10.1016/j.apmr.2007.11.022 · Source: PubMed


    To describe the use of botulinum toxin type A (BTX-A) in radiation fibrosis syndrome (RFS).
    Retrospective case series.
    A large tertiary care cancer center.
    Twenty-three consecutive patients treated for sequelae of RFS with BTX-A.
    Not applicable.
    A description of the components of RFS thought to benefit from BTX-A injections and the patient's self-report of benefit from those injections.
    The sequelae of RFS for which BTX-A injection was thought to be indicated include radiation-induced cervical dystonia in 18 (78%), trigeminal nerve or cervical plexus neuralgia in 10 (43%), trismus in 7 (30%), migraine in 3 (13%), and thoracic pain in 1 (4%) patient. Most (87%) patients self-reported benefit from the injections.
    Initial clinical experience with the use of BTX-A as adjunctive treatment for select neuromuscular and musculoskeletal complications of RFS in a variety of cancer patients has been encouraging. Well-designed prospective studies are needed to clarify the potential beneficial role of BTX-A in specific sequelae of RFS.

    Similar publications